DAMGO
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
DAMGO is a selective peptide agonist of the µ-opioid receptor (Ki = 1.18, 1430, and 213 nM for human µ-, δ-, and κ-opioid receptors, respectively) [1].
Opioid receptors are members of the class A family of G protein-coupled receptors (GPCRs), which transduce signals via heterotrimeric G proteins on the inner surface of the plasma membrane, leading to intracellular signaling cascades involved in many aspects of cellular function. Four opioid receptor types exist [μ, δ, κ, and opioid receptor-like 1 (ORL1)], among which the μ-opioid receptor has been most explored as its agonists are used to treat chronic pain [2].
In C6μ cell membranes, DAMGO at 10 µM produced a 250% stimulation of [35S]GTPγS binding above basal activity through the µ-opioid receptors, with an EC50 of 222 nM [2]. In mouse vas deferens (MVD), DAMGO strongly inhibited the electrically-evoked MVD muscle contractions in concentration dependent manner, with EC50 value of 238.47 nM [3].
In the rat late permanent visceral pain model, DAMGO produced dose-dependent antinociceptive action, with potency similar to that of morphine when given i.p. to the same site where acetic acid was injected. The calculated ED50 values were 238.57 nmol/kg for morphine and 289.52 nmol/kg for DAMGO [4].
References:
[1]. Zhao G M, Qian X, Schiller P W, et al. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at µ, δ, and κ opioid receptors. Journal of Pharmacology and Experimental Therapeutics, 2003, 307(3): 947-954.
[2]. Burford N T, Clark M J, Wehrman T S, et al. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(26): 10830-10835.
[3]. Lacko E, Varadi A, Rapavi R, et al. A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy. Current Medicinal Chemistry, 2012, 19(27): 4699-4707.
[4]. Al-Khrasani M, Lackó E, Riba P, et al. The central versus peripheral antinociceptive effects of μ-opioid receptor agonists in the new model of rat visceral pain. Brain Research Bulletin, 2012, 87(2-3): 238-243.
Physical Appearance | White lyophilised solid |
Storage | Desiccate at -20°C |
M.Wt | 513.7 |
Cas No. | 78123-71-4 |
Formula | C26H35N5O6 |
Solubility | ≥40.7 mg/mL in EtOH; ≥40.7 mg/mL in H2O; ≥42.2 mg/mL in DMSO |
Chemical Name | (S)-2-amino-N-((R)-1-((2-(((S)-1-((2-hydroxyethyl)amino)-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-2-oxoethyl)amino)-1-oxopropan-2-yl)-3-(4-hydroxyphenyl)propanamide |
SDF | Download SDF |
Canonical SMILES | O=C([C@H](CC1=CC=CC=C1)N(C)C(CNC([C@@H](C)NC([C@H](CC(C=C2)=CC=C2O)N)=O)=O)=O)NCCO |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次: